De Motu Cordis Expands Global IP Portfolio
De Motu Cordis grows its IP portfolio to 28 patents, fortifying innovations in emergency medicine for anaphylaxis with their drug-device dry powder inhaler.
De Motu Cordis Expands Global IP Portfolio
Medicine And Healthcare
Leading into J.P. Morgan Healthcare Week, De Motu Cordis (DMC) is pleased to announce the continued growth of our global intellectual property (IP) portfolio, now encompassing 29 granted patents across six patent families.
As a clinical-stage pharmaceutical company based in Brisbane, Australia, DMC is advancing the development of a drug-device dry powder inhaler for the treatment of anaphylaxis and other emergency medicine applications.
Our recently granted patents strengthen protection for the core technologies behind our proprietary device and novel formulation.
Over the past year, we have more than doubled the number of granted patents in key markets, including the United States, Europe, Asia, and Australia.
Looking ahead, we plan to file additional patent applications to safeguard new innovations within our platform technology, reinforcing our commitment to creating transformative solutions in emergency medicine.
About DMC
“DMC is a clinical stage pharma company.”
DMC was founded in Brisbane, Australia by Professor John Fraser, an Intensivist and groundbreaking clinician, researcher, and company founder. John is also founder of the Critical Care Research Group and is a co-founder of BIVACOR Pty Ltd. John co-founded the COVID-19 Critical Care Consortium that facilitated collecting over 35 million data points from ICU units worldwide and aided in the development of treatment pathways.
Since inception, DMC has raised over US $21m in Seed rounds primarily in Australia. The majority of funding to date have been secured via the Queensland Business Development Fund, high net worth individuals and Australian family offices. A Series A financing round is planned for H2 2025, which will ideally be anchored by a US based VC.
De Motu Cordis Founder and CMO, Professor John Fraser Awarded Order of Australia
De Motu Cordis CMO, Prof. John Fraser, awarded the Order of Australia for his contributions to medicine and critical care research.
De Motu Cordis (DMC) receives a letter of support from Food Allergy Research and Education (FARE)
On November 1, 2024, DMC received a formal letter of support from Food Allergy Research and Education (FARE), the largest nonprofit organisation in the U.S. committed to enhancing the quality of life and health for individuals with food allergies through innovative research, education, and advocacy.